Funding to Drive Nanoscale Technology for Healthcare - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Funding to Drive Nanoscale Technology for Healthcare


ePT--the Electronic Newsletter of Pharmaceutical Technology

The UK’s Technology Strategy Board has partnered with the Engineering and Physical Sciences Research Council (EPSRC) to invest as mush as £9 million ($14.2 million) in grant funding with the aim of bringing proof-of-concept ideas to pilot technology demonstration for healthcare.

The Technology Strategy Board is a UK government body sponsored by the Department for Business, Innovation, and Skills (BIS), and charged with bringing together the business community, researchers, and the public sector to meet market needs and build the future economy. The specific goal of this project is to ensure that the healthcare sector adopts emerging novel nanoscale technology-enabled solutions by providing support to a commercialization route through innovative businesses.

The focus is on highly innovative, collaborative research in nanoscale technology-enabled solutions that deliver therapeutics and diagnostics. About £3 million ($4.75 million) is available for businesses (through the Technology Strategy Board), and £6 million ($9.49 million) is available for participation by academia (through the EPSRC). Collaborations to be considered must be business-led, but draw at least one partner from large or small businesses, academia, research, and technology organizations, or not-for-profit organizations. Projects can receive between £500,000 ($791,200) and £2 million ($3.16 million).

The Technology Strategy Board will accept applications from Nov. 1, 2011 until Dec. 13, 2011. Further information can be found here.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here